Valneva receives first chikungunya vaccine approval after two month delay to FDA review

Val­ne­va re­ceived the first reg­u­la­to­ry ap­proval for a chikun­gun­ya virus vac­cine with an FDA ac­cel­er­at­ed nod on Thurs­day night.

The green light marks a key win for the Eu­ro­pean biotech, which will get more than a year’s head start on po­ten­tial com­peti­tor Bavar­i­an Nordic and could snag about $100 mil­lion by sell­ing the pri­or­i­ty re­view vouch­er that it gets as part of the ap­proval. It al­so serves as a boon to Val­ne­va as the com­pa­ny works through hur­dles with an­oth­er of its late-stage in­ves­ti­ga­tion­al vac­cines for Ly­me dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.